Natus Medical Announces 2017 Annual and First Quarter Financial Guidance
Jan 09, 2017 12:01 pm UTC| Business
Updates Fourth Quarter 2016 RevenueAnnounces Fourth Quarter 2016 Financial Results Conference Call Date PLEASANTON, Calif., Jan. 09, 2017 -- Natus Medical Incorporated (NASDAQ:BABY) today announced its financial...
Noble Energy Closes Delaware Basin Acquisitions Totaling 7,200 Net Acres
Jan 09, 2017 12:01 pm UTC| Business
Houston, Jan. 09, 2017 -- Noble Energy, Inc. (NYSE: NBL) (“Noble Energy” or “the Company”) today announced that the Company has finalized the previously announced bolt-on transactions which have added approximately...
AxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2016 Revenue
Jan 09, 2017 12:01 pm UTC| Business
Q4 Revenue will be at least $11.3 million, representing 45% growth over prior year 2016 Revenue will be at least $41.0 million, representing 50% growth over prior year ALACHUA, Fla., Jan. 09, 2017 -- AxoGen, Inc....
Jan 09, 2017 12:01 pm UTC| Business
Critical Phase 3 study design input received from U.S. Food and Drug Administration (“FDA”): Agreed to a randomized open-label, two-arm clinical study to include a LPCN 1107 arm and a comparator intramuscular (“IM”) arm...
Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration
Jan 09, 2017 12:00 pm UTC| Business
LEXINGTON, Mass., Jan. 09, 2017 -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today...
Southcross Energy Announces Leadership Change
Jan 09, 2017 12:00 pm UTC| Business
DALLAS, Texas, Jan. 09, 2017 -- Southcross Energy Partners, L.P. (NYSE:SXE) (“Southcross”) and Southcross Holdings LP (“Holdings”) announced today a consolidation of the roles of Chairman and Chief Executive Officer of...
Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO
Jan 09, 2017 12:00 pm UTC| Business
Austin, Texas, Jan. 09, 2017 -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of injectable drugs, announced that Mr. Paul R....